Reported about 22 hours ago
Investors may want to consider Pfizer and Target as two beaten-down stocks with potential for long-term growth. Pfizer, despite facing challenges from declining COVID-19 product sales and patent expirations, is bolstered by a strong pipeline of new drugs and acquisitions. Target is navigating difficulties due to shifting consumer priorities but aims for profitable growth by expanding its services and store count. Both companies offer attractive dividends, making them potential buys for investors looking to capitalize on dips.
Source: YAHOO